Shares of Fate climbed nearly 4% in premarket trading after it announced positive interim data from a Phase I study of FT516 for patients with relapsed / refractory B-cell lymphoma.

With the 2021 American Society of Clinical Oncology meeting held late last week, there is plenty of clinical trial news.

An ugly symbol of racism appears to have reared its head at a Merck facility in North Carolina. The pharma giant is investigating reports of a noose found hanging at a construction project on the 262-acre facility.

Novartis flexed its clinical muscles over the weekend, announcing results from multiple studies including different types of cancer and kidney disease.

Today, the U.S. Food and Drug Administration approved Wegovy (semaglutide) injection (2.4 mg once weekly) for chronic weight management in adults with obesity or overweight with at least one weight-related condition (such as high blood pressure, type 2 diabetes, or high cholesterol), for use in addition to a reduced calorie diet and increased physical activity.

REGEN-COV's 1,200 mg dose is authorized to treat mild-to-moderate COVID-19 in adults and children 12 years and older who weigh 40 kilograms or more.

It didn’t take too long before a lawsuit was filed over Bristol Myers Squibb’s failure to meet a deadline for a $9 Contingent Value Rights agreement tied to the company’s merger with Celgene.

On June 5, the world marks the 40th anniversary of the HIV epidemic. Biopharma researchers continue to develop safe and effective treatments with an eye to a potential cure.

With the 2021 American Society of Clinical Oncology Annual Meeting now in high gear, there is plenty of news. Here’s a look at just some of the most recent stories.

Importantly, the researchers recovered virus that they were able to culture, indicating a high risk for transmissibility.

​The three companies will aim to develop their different programs such as Stablix TPS platform, Stellanova's focused on targeting pro-tumorigenic effects, and Amyl's development of preclinical therapeutic candidates.

Bayer will nab exclusive rights to a differentiated alpha radionuclide, actinium-225 investigational compound, and a small molecule targeting prostate-specific membrane antigen.

Nanobiotix is developing a way for its locally-injected radioenhancer for solid tumors to treat metastasized cancers, in combination with checkpoint inhibitors, and also deliver results distally.

Bayer, like many biopharma companies, is presenting study results at the 2021 American Society of Clinical Oncology (ASCO) Annual meeting being held online June 4-8, 2021.

Every week there are numerous scientific studies published. Here’s a look at some of the more interesting ones.

Biopharma and life sciences organizations strengthen their leadership teams and board with these Movers & Shakers.

While several countries rely on Sinovac Biotech to end the pandemic, concerns regarding the shot’s efficacy continue to shroud the vaccine. Currently, it is the second most used vaccine worldwide.

The experimental drug TEMPOL may be a promising oral antiviral treatment for COVID-19, suggests a study of cell cultures by researchers at the National Institutes of Health. TEMPOL can limit SARS-CoV-2 infection by impairing the activity of a viral enzyme called RNA replicase. The work was led by researchers at NIH's Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD). The study appears in Science.

Physiologically, milk contains biocomponents that are highly protective against infections. In light of this, the AGR-149-Infectious Diseases group at the University of Cordoba's Department of Animal Health is doing research that focuses on cow's milk as a possible source of COVID-19 control. The results have been published, partially, in the journal Frontiers in Immunology.

The nation’s top science adviser believes the country’s renewed enthusiasm for science may pave the way for plug-and-play vaccines that can nullify the next pandemic before it starts.